Cargando…

Phase III randomised controlled trial on PSMA PET/CT guided hypofractionated salvage prostate bed radiotherapy of biochemical failure after radical prostatectomy for prostate cancer (PERYTON-trial): study protocol

BACKGROUND: Salvage external beam radiotherapy (sEBRT) for patients with a biochemical recurrence (BCR) after radical prostatectomy provides a 5-year biochemical progression-free survival up to 60%. Multiple studies have shown that dose escalation to the primary prostate tumour improves treatment ou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Staal, F. H. E., Janssen, J., Brouwer, C. L., Langendijk, J. A., Ng Wei Siang, K., Schuit, E., de Jong, I. J., Verzijlbergen, J. F., Smeenk, R. J., Aluwini, S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013125/ https://www.ncbi.nlm.nih.gov/pubmed/35428210 http://dx.doi.org/10.1186/s12885-022-09493-5

Ejemplares similares

Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy (ADOPT): study protocol for a randomised phase III trial
por: Janssen, J., et al.
Publicado: (2022)

Skeletal (18)F-PSMA-1007 uptake in prostate cancer patients
por: Janssen, Jorinde, et al.
Publicado: (2023)

Dose evaluation of inter- and intra-fraction prostate motion in extremely hypofractionated intensity-modulated proton therapy for prostate cancer
por: Feng, Sen-Quan, et al.
Publicado: (2023)

Hypofractionated helical intensity-modulated radiotherapy of the prostate bed after prostatectomy with or without the pelvic lymph nodes - the PRIAMOS trial
por: Krause, Sonja, et al.
Publicado: (2012)

(68)Ga-PSMA-PET screening and transponder-guided salvage radiotherapy to the prostate bed alone for biochemical recurrence following prostatectomy: interim outcomes of a phase II trial
por: Bowden, Patrick, et al.
Publicado: (2021)

The effects of PSA kinetics on the outcome of hypofractionated salvage radiotherapy for biochemical recurrence of prostate cancer after prostatectomy
por: Ishikawa, Hitoshi, et al.
Publicado: (2020)

Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy
por: Oehus, Ann-Kathrin, et al.
Publicado: (2020)

Hypofractionation trials and radiobiology of prostate cancer
por: Gulliford, Sarah, et al.
Publicado: (2017)

Safety and efficacy of salvage low-dose-rate brachytherapy for prostate bed recurrences following radical prostatectomy
por: Kumar, Aryavarta M.S., et al.
Publicado: (2015)

Peryton: a manual collection of experimentally supported microbe-disease associations
por: Skoufos, Giorgos, et al.
Publicado: (2020)

Outcomes and Prediction Models for Exclusive Prostate Bed Salvage Radiotherapy among Patients with Biochemical Recurrence after Radical Prostatectomy
por: Tseng, Chi-Shin, et al.
Publicado: (2021)

Intra-fraction displacement of the prostate bed during post-prostatectomy radiotherapy
por: Bell, Linda J., et al.
Publicado: (2021)

Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial
por: Privé, Bastiaan M., et al.
Publicado: (2021)

A prospective phase II study of prostate-specific antigen-guided salvage radiotherapy and (68)Ga-PSMA-PET for biochemical relapse after radical prostatectomy – The PROPER 1 trial
por: Gunnlaugsson, Adalsteinn, et al.
Publicado: (2022)

Randomized prospective phase III trial of (68)Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]
por: Calais, Jeremie, et al.
Publicado: (2019)

Oligometastases in prostate cancer: Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT
por: Baumann, René, et al.
Publicado: (2017)

Impact of (68)Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy
por: Bluemel, Christina, et al.
Publicado: (2016)

Postoperative or Salvage Proton Radiotherapy for Prostate Cancer After Radical Prostatectomy
por: Kharod, Shivam M., et al.
Publicado: (2021)

The Role of Salvage Radical Prostatectomy in Patients with Radiation-Resistant Prostate Cancer
por: Drobner, Jake, et al.
Publicado: (2023)

Three Months’ PSA and Toxicity from a Prospective Trial Investigating STereotactic sAlvage Radiotherapy for Macroscopic Prostate Bed Recurrence after Prostatectomy—STARR (NCT05455736)
por: Francolini, Giulio, et al.
Publicado: (2023)

Correction to: Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]
por: Calais, Jeremie, et al.
Publicado: (2019)

Outcomes of salvage radical prostatectomy after initial irreversible electroporation treatment for recurrent prostate cancer
por: van Riel, Luigi A.M.J.G., et al.
Publicado: (2022)

PSMA-positive nodal recurrence in prostate cancer: Salvage radiotherapy is superior to salvage lymph node dissection in retrospective analysis
por: Schmidt-Hegemann, Nina-Sophie, et al.
Publicado: (2020)

Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy
por: Rogowski, Paul, et al.
Publicado: (2021)

Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial
por: Privé, Bastiaan M., et al.
Publicado: (2020)

Long-term economic value of hypofractionated prostate radiation: Secondary analysis of a randomized trial
por: Voong, K. Ranh, et al.
Publicado: (2017)

Salvage radiotherapy after radical prostatectomy: Long-term results of urinary incontinence, toxicity and treatment outcomes
por: van Dessel, Lisanne F., et al.
Publicado: (2018)

Outcomes of laparoscopic salvage radical prostatectomy after primary treatment of prostate cancer
por: Catarino, Raquel, et al.
Publicado: (2022)

Hypofractionated radiotherapy for prostate cancer
por: Hegemann, Nina-Sophie, et al.
Publicado: (2014)

Moderate hypofractionation for prostate cancer
por: Arcangeli, Stefano, et al.
Publicado: (2017)

Moderate hypofractionation for prostate cancer
por: Lee, W. Robert, et al.
Publicado: (2018)

Patient reported toxicity and quality of life after hypofractionated high-dose intensity-modulated radiotherapy for intermediate- and high risk prostate cancer
por: Houben, Jeroen, et al.
Publicado: (2021)

Prostate-Specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death
por: Tilki, Derya, et al.
Publicado: (2023)

The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy—a multicenter retrospective analysis
por: Spohn, Simon K. B., et al.
Publicado: (2022)

Quantitative MRI Changes During Weekly Ultra-Hypofractionated Prostate Cancer Radiotherapy With Integrated Boost
por: van Schie, Marcel A., et al.
Publicado: (2019)

Phase II Trial of Pure Hypofractionated Radiotherapy in the Treatment of Localized Carcinoma of the Prostate
por: Gopaul, Darin, et al.
Publicado: (2018)

PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials
por: Ramnaraign, Brian, et al.
Publicado: (2023)

Salvage surgery for residual disease following unsuccessful laparoscopic radical prostatectomy for prostate cancer
por: Tashiro, Kojiro, et al.
Publicado: (2020)

Feasibility and Outcome of PSMA-PET-Based Dose-Escalated Salvage Radiotherapy Versus Conventional Salvage Radiotherapy for Patients With Recurrent Prostate Cancer
por: Vogel, Marco M. E., et al.
Publicado: (2021)

Comparison of hypofractionation and standard fractionation for post-prostatectomy salvage radiotherapy in patients with persistent PSA: single institution experience
por: Murgic, Jure, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6sjukm4mp7qje30f7peumc01ti